Abstract
To determine whether angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (ACEI/ARB) initiation in people with diabetes is monitored as recommended by recent guidelines and the incidence of associated adverse renal events.
| Original language | English |
|---|---|
| Pages (from-to) | 69-76 |
| Number of pages | 8 |
| Journal | Scottish Medical Journal |
| Volume | 58 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - May 2013 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Aged
- Aged, 80 and over
- Analysis of Variance
- Angiotensin Receptor Antagonists
- Angiotensin-Converting Enzyme Inhibitors
- Creatinine
- Diabetes Mellitus, Type 2
- Drug Monitoring
- Electrolytes
- Female
- General Practice
- Humans
- Hyperkalemia
- Logistic Models
- Male
- Middle Aged
- Retrospective Studies
Fingerprint
Dive into the research topics of 'Monitoring and adverse events in relation to ACE inhibitor/angiotensin receptor blocker initiation in people with diabetes in general practice: a population database study'. Together they form a unique fingerprint.Equipment
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver